Outset Medical, Inc.
OMNasdaqHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $119.5M | $113.7M | $130.4M | $115.4M | $102.6M | $7.2M |
| Operating income | −$66.7M | −$113.4M | −$169.8M | −$161.0M | −$130.5M | −$117.5M |
| Net income | −$81.7M | −$128.0M | −$172.8M | −$163.0M | −$131.9M | −$20.6M |
| Total assets | $264.5M | $275.8M | $313.8M | $400.1M | $463.5M | $403.8M |
| Total liabilities | $137.5M | $249.0M | $190.9M | $154.1M | $89.4M | $75.2M |
| Equity | $127.0M | $26.8M | $122.9M | $246.0M | $374.1M | $328.6M |
| EPS (diluted) | $-5.37 | $-36.96 | $-52.28 | $-3.38 | $-2.89 | $0.74 |
| Shares out. | 53.9M | 50.5M | 48.6M | 47.4M | 42.8M | 42.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −55.8%
- Net margin
- −68.3%
- Return on equity
- −64.3%
- Return on assets
- −30.9%
- Return on capital (ROCE)
- −29.4%
- Liabilities / assets
- 52.0%
- Debt / equity
- 1.08×
- Book value / share
- $2.36
- Revenue growth (YoY)
- 5.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.87distress
- Accruals / assets
- −13.4%clean
- Beneish M-Score
- -3.21normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Brottem John L.Officer — General Counsel | May 15, 2026 | Sell | 2,638 | $3.70 |
| Leonard Braden Michael10% owner | May 15, 2026 | Option exercise | 323,000 | $5.00 |
| Leonard Braden Michael10% owner | May 8, 2026 | Option exercise | 197,600 | $5.00 |
| Elliott Derick A.Officer — EVP, Commercial | Apr 6, 2026 | Grant | 96,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.1M | 9.5 | +2.2% |
| Apr 30, 2026 | 2.0M | 15.4 | -3.7% |
| Apr 15, 2026 | 2.1M | 20.1 | +7.3% |
| Mar 31, 2026 | 1.9M | 13.3 | -7.1% |
| Mar 13, 2026 | 2.1M | 8.0 | +9.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 29, 2026
- Results of operationsMay 7, 2026
- Results of operationsFeb 11, 2026
- Other material eventJan 27, 2026
- Results of operations · Director / officer change · Regulation FD disclosureJan 12, 2026
- Results of operationsNov 10, 2025
- Results of operationsAug 6, 2025
- Director / officer change · Shareholder vote · Regulation FD disclosureJun 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 29, 2026
- SDMay 29, 2026
- 4PRIMARY DOCUMENTMay 19, 2026
- 4PRIMARY DOCUMENTMay 19, 2026
- 4PRIMARY DOCUMENTMay 19, 2026
- SCHEDULE 13G/AMay 18, 2026
- 4May 18, 2026
- 144May 15, 2026
- 144May 15, 2026
- 144May 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 12, 2026
- 4May 12, 2026
- 10-QMay 7, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.